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Introduction
Observational studies associate excess weight at breast can-
cer (BC) diagnosis, and weight gain after diagnosis with 
increased BC specific and all cause mortality1 and decreased 
quality of life.2 These data suggest weight loss or prevent-
ing weight gain will improve the outcome for BC patients. 
Most previous diet and exercise trials have targeted behav-
ior change after completion of adjuvant chemotherapy and 
radiotherapy.3 The American Society of Clinical Oncology 
guidelines recognize that many patients with different can-
cer types will gain weight during and after treatment and 
that some patients may feel able to instigate lifestyle change 
during treatment.4 However, although Survivorship Care 
Plans, which are popular in the United States, promote 
healthy lifestyles after diagnosis, only the minority include 
information on preventing weight gain during treatment.5 In 
the United Kingdom, the “Living With and Beyond Cancer” 
initiative suggests promoting physical activity and weight 
management, but the focus is after treatment.6 Treatment-
associated weight gain is currently seen in 70% of patients.7 
Intervening at the time of diagnosis or early on during adju-
vant treatment may provide a “teachable moment” when 
women may be responsive to making beneficial lifestyle 
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Abstract
Excess weight at breast cancer diagnosis and weight gain during treatment are linked to increased breast cancer specific and 
all-cause mortality. The Breast—Activity and Healthy Eating After Diagnosis (B-AHEAD) trial tested 2 weight loss diet and 
exercise programmes versus a control receiving standard written advice during adjuvant treatment. This article identifies 
differences in characteristics between patients recruited from the main trial site to those of the whole population from 
that site during the recruitment period and identifies barriers to recruitment. A total of 409 patients with operable breast 
cancer were recruited within 12 weeks of surgery. We compared demographic and treatment factors between women 
recruited from the main trial coordinating site (n = 300) to the whole breast cancer population in the center (n = 532). 
Uptake at the coordinating site was 42%, comparable to treatment trials in the unit (47%). Women recruited were younger 
(55.9 vs 61.2 years, P < .001), more likely to live in least deprived postcode areas (41.7% vs 31.6%, P = .004), and more likely 
to have screen-detected cancers (55.3% vs 48.7%, P = .026) than the whole breast cancer population. The good uptake 
highlights the interest in lifestyle change around the time of diagnosis, a challenging time in the patient pathway, and shows 
that recruitment at this time is feasible. Barriers to uptake among older women and women with a lower socioeconomic 
status should be understood and overcome in order to improve recruitment to future lifestyle intervention programs.
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changes. This timing provides an opportunity to prevent 
treatment-associated weight gain,8,9 which would otherwise 
be missed.
The Breast—Activity and Healthy Eating After 
Diagnosis (B-AHEAD) trial aimed to define a cost effective 
diet and exercise weight control intervention to be offered 
to patients at the time of diagnosis and implemented during 
adjuvant treatment. The intention was to prevent gains in 
body fat in healthy weight women, and achieve fat loss in 
overweight women. Patients were invited to the study 
around the time of surgery, and were asked to adhere to the 
programmes during adjuvant treatment and for 12 months 
after diagnosis.
Here we report uptake to the trial across the former 
Greater Manchester and Cheshire Cancer Research Network 
(GMCCRN), and the characteristics of patients recruited 
from the main trial site compared to those of the whole pop-
ulation from that site. These data describe the population to 
which the B-AHEAD trial outcomes, to be published in a 
future article, will be applicable. Data on uptake to weight 
control programmes at the time of diagnosis will help 
improve recruitment success in future clinical trials and 
programmes in clinical practice.
Materials and Methods
A total of 409 women from 9 hospitals in the GMCCRN 
were recruited over 29 months. Written informed consent 
was obtained from all individual participants included in 
the study. The trial was coordinated at the University 
Hospital of South Manchester (UHSM), which was also the 
main recruiting site (ISRCTN number 68576140).
Inclusion and exclusion criteria were as follows.
Inclusion Criteria
•• Within 12 weeks of primary breast or axillary sur-
gery for early BC (invasive or in situ)
•• Any age
•• Any weight (as the programs aimed to tackle existing 
weight problems and prevent weight gain that occurs 
in women of any weight)
•• Able to understand written instructions
Exclusion Criteria
•• Metastatic or inoperable disease
•• Physical or mental health conditions: which recruit-
ing staff decided either deemed subjects inappropri-
ate to approach, or could impair compliance to the 
diet and exercise programs
•• Regularly taking medication known to affect body 
composition, for example, daily glucocorticoids (2-3 
days glucocorticoids with chemotherapy could be 
included)
•• Women who have received neoadjuvant chemother-
apy or neoadjuvant endocrine therapy
Women were made aware of the trial either before their 
surgery or at their initial postsurgery appointment by their 
breast surgeon or GMCCRN nurse.
Trial appointments at baseline, 6 and 12 months at 
UHSM measured the primary (weight, body fat [dual energy 
X-ray absorptiometry]) and secondary outcome measures 
(waist and hip circumference, insulin sensitivity, lipids, fit-
ness [12-minute walk test on treadmill], and adherence 
[7-day food and activity diaries]). Participants were offered 
reimbursement for travel costs, for example, petrol, park-
ing, public transport or taxi costs, and volunteer drivers 
were arranged if required.
Participants were randomized to one of the following:
1. Control group: standard written diet and exercise 
advice only (n = 138)
2. 12-week home-based diet and exercise program 
with fortnightly telephone calls and mailed informa-
tion (n = 134)
3. 12-week supervised community-based programme 
with weekly classes held in 5 locations around 
Greater Manchester (n = 137)
Recruiting hospitals submitted monthly records on num-
bers of noneligible women, and eligible women declining 
entry, and the reasons for both. Uptake figures were most 
complete for UHSM, the main recruiting site. We compared 
demographic and treatment factors among women recruited 
to the B-AHEAD trial to the whole BC population at UHSM 
during the recruitment period to determine patterns of 
uptake. We were unable to directly compare those recruited 
with those who declined to enter the study as we were 
unable to collect data on women who did not consent to join 
the study. Data were analyzed by independent-samples t 
test, Pearson’s chi-squared or Fisher’s exact test using IBM 
SPSS version 20 (IBM, Armonk, NY, USA).
Results
During the 29-month recruitment phase at UHSM, 1116 
women were screened, 410 did not meet the inclusion crite-
ria (Table 1), 406 women declined to participate (Table 2), 
and 300 eligible women were recruited (42% of eligible 
women). The main reasons for exclusion were the presence 
of comorbidities (38.3%), or that patients had received neo-
adjuvant chemotherapy (31.2%). Unfortunately, 14.4% of 
women could not be contacted within the limit of 12 weeks 
after surgery.
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Almost 30% of eligible women did not wish to join the 
trial because of the extra hospital visits, blood samples or 
scans involved (Table 2). Another 12.8% were anxious or 
depressed around the time of diagnosis, or could not cope 
with having to make another decision. A significant number 
(7.4%) declined due to transport problems despite the offer 
of reimbursement of travel costs.
Patient, tumor, and treatment characteristics of the 300 
women joining the trial from UHSM were compared with 
the 532 patients receiving surgery at UHSM during the mid-
dle year of trial recruitment (Table 3). Women recruited to 
B-AHEAD were younger, with significantly fewer women 
aged older than 70 years. They were more likely to have 
screen-detected cancers and breast conserving surgery and 
were more likely to live in the least deprived postcode areas. 
The distribution of ethnicities among women who joined 
the trial was similar to that of the wider UHSM population. 
Uptake was comparable across all body mass index (BMI) 
categories and among women scheduled to have chemo-
therapy. Distance from the hospital did not influence uptake.
Discussion
Our data do not support the previously highlighted concern 
cited among breast cancer health professionals that patients 
would not welcome being approached regarding lifestyle 
interventions at the time of diagnosis.11 The recruitment rate 
of 42% of eligible women is comparable to uptake to treat-
ment trials in our unit (47%)12 despite the fact that the diet 
and exercise trial required an additional commitment from 
patients to change behaviors and attend 3 trial assessment 
appointments. Thus, BC patients appear equally interested 
to join lifestyle and treatment interventions at the time of 
diagnosis and commencing adjuvant treatment. At the time 
of recruitment to the B-AHEAD trial, the main recruiting 
center had 13 other surgical and treatment trials also open to 
recruitment. Though not supported by data, these studies 
could have affected recruitment to the B-AHEAD trial, not 
because they precluded women from joining the study, but 
because clinicians may not have wished to overburden a 
patient to consider a lifestyle study as well as a treatment or 
surgical study. The good uptake may be consistent with the 
hypothesis that a BC diagnosis may be a “teachable moment” 
when women may be responsive to making beneficial life-
style changes.8,9 Of 531 early stage breast cancer patients in 
a US survey, 57% indicated that they would welcome health 
promotion interventions “at diagnosis or soon after.”13
Table 1. Reasons for UHSM Patients Being Deemed Not 
Eligible for the B-AHEAD Trial.
Reason for Exclusion n % of Total
Breast cancer–related issues: 160 39.0
 Neoadjuvant treatment 128 31.2
 Metastases 32 7.8
Comorbidities: 157 38.3
 Mental health conditions 41 10.0
 Musculoskeletal diagnoses 19 4.6
 Cardiac diagnoses 18 4.4
 Diabetes on insulin 5 1.2
 Digestive disorders (eg, IBD or 
Crohn’s disease)
3 0.7
 Respiratory diagnoses 2 0.5
 Daily glucocorticoids 1 0.2
 Other comorbidities 68 16.6
Recruitment issues: 80 19.5
 Unable to contact patient within 
12 weeks of surgery
59 14.4
 Language barriers 13 3.2
 Infection postoperation 5 1.2
 Already recruited to another trial 3 0.7
Unknown reason 13 0.3
Total 410
Abbreviations: UHSM, University Hospital of South Manchester; 
B-AHEAD, Breast—Activity and Healthy Eating After Diagnosis; IBD, 
inflammatory bowel disease.
Table 2. Reasons for Eligible UHSM Patients Declining Entry to 
the B-AHEAD Trial.
Reason for Eligible Patients Declining 
Trial Entry n % of total
Factors related to trial recruitment 
soon after diagnosis
173 42.6
 Doesn’t want extra hospital visits, 
blood samples, or scans
121 29.8
 Can’t cope with making another 
decision at this time
33 8.1
 Patient too anxious/depressed at this 
time
19 4.7
Trial related: 129 31.8
 Has too many other commitments 60 14.8
 Does not wish to take part in a 
research trial
34 8.4
 Patient does not want to be 
randomized
5 1.2
 Transport problems with attending 
additional trial appointments
30 7.4
Diet and/or exercise related: 24 5.9
 Already has healthy lifestyle 
according to participant
11 2.7
 Does not want to go on a diet/do 
exercise
4 1.0
 Patient declined information about 
the trial/not interested in trial
9 2.2
Reason not disclosed 80 19.7
Total 406
Abbreviations: UHSM, University Hospital of South Manchester; 
B-AHEAD, Breast—Activity and Healthy Eating After Diagnosis.
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This article is one of the few to report uptake to weight 
control trials among BC patients during adjuvant treatment. 
Three diet and exercise trials among women scheduled to 
have adjuvant chemotherapy reported uptake figures of 
45%,14 65%,15 and 81%.16 However, these trials did not 
clarify whether they approached all eligible women within 
a certain time frame as we have done, or if they used a 
selective approach that would have given a higher level of 
recruitment. Djuric et al17 recruited 56% of eligible women 
to their randomized diet and exercise trial during chemo-
therapy where recruitment was incentivized with a $25 pay-
ment for each of the 3 study visits. Exercise-only trials 
during adjuvant treatment have reported uptakes of 63% in 
Australia,18 47% in the United States,19 44% in the 
Netherlands,20 and 11% in the United Kingdom.21 
Participants on the Australian exercise trial were on average 
Table 3. B-AHEAD Population Compared With the Total UHSM BC Population.
B-AHEAD Population Recruited 
From UHSM 2009-2011  
(N = 300)
Total UHSM Population 2010 
Including Those Recruited  
(N = 532) Pa
Age, years, at recruitmentb 55.9 (10.1) 61.2 (12.8) <.001
Age >70 yearsc 22 (7.3) 118 (22.1) <.001
Distance: home to recruiting center (miles)b 9.8 (7.0) 10.3 (7.1) .420
BMI at recruitment (kg/m2)b 27.5 (5.5) 27.1 (5.6) .410
Screen-detected BCc 166 (55.3) 259 (48.7) .026
Ethnicityd
 White—all types 279 (93.3) 461 (86.7) .411
 Black—all types 8 (2.7) 9 (1.7)
 Asian—all types 10 (3.3) 25 (5.0)
 Mixed—all types 1 (0.3) 3 (0.6)
 Chinese 0 (0.0) 5 (0.9)
 Other 1 (0.3) 2 (0.4)
 Missing 1 (0.3) 27 (5.1)
BMI categoryd
 Underweight (<18.5 kg/m2) 4 (1.3) 9 (1.5) .898
 Healthy weight (18.5-24.9 kg/m2) 108 (36) 192 (36.2)
 Overweight (25-29.9 kg/m2) 105 (35) 173 (32.5)
 Obese (≥30kg/m2) 83 (27.7) 158 (29.8)
Index of multiple deprivationc,e
Greater Manchester quintiles
 1 (least deprived) 125 (41.7) 168 (31.6) .004
 2 60 (20.0) 94 (17.6)
 3 42 (14.0) 84 (15.8)
 4 35 (11.7) 70 (13.1)
 5 (most deprived) 38 (12.7) 116 (21.8)
Tumor type and gradec
 Invasive/in situ carcinoma 256 (85.3) / 44 (14.7) 444 (83.5) / 88 (16.5) .447
 Grade 3 carcinoma 73 (24.3) 157 (29.5) .170
 Estrogen receptor positive 252 (83.9) 431 (81.1) .298
Surgery typec
 Mastectomy 95 (31.7) 208 (39.1) .032
 Axillary node clearance 58 (19.3) 112 (21.1) .555
Treatmentc
 Chemotherapy 88 (29.3) 147 (27.6) .601
 Radiotherapy 213 (71.0) 325 (61.1) .004
Abbreviations: BMI, body mass index; BC, breast cancer; UHSM, University Hospital of South Manchester; B-AHEAD, Breast—Activity and Healthy 
Eating After Diagnosis.
aP values in boldface indicate statistical significance (P < .05).
bMean (SD), independent samples t test.
cn (% of group), Pearson chi-squared.
dn (% of group), Fisher’s exact test.
eIndices of Deprivation 2007 Layer Super Output Area Scores were identified from participant postcodes via Geoconvert.10
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7 years younger than the general BC population, a finding 
similar to the B-AHEAD trial.
An important finding was the comparable uptake among 
women scheduled for chemotherapy versus those who were 
not. Weight gain is a particular problem for chemotherapy 
patients7 and one might perceive this group to be more 
reluctant to join such a trial due to higher anxiety levels and 
treatment burden.22 Factors affecting BC prognosis such as 
grade or tumor type did not influence uptake. We did, how-
ever, find a lower uptake among patients with a mastec-
tomy, which was previously reported in the PACES study, 
an exercise study during adjuvant chemotherapy for breast 
cancer.20
The lower average age of recruited patients in this trial 
and fewer women older than 70 years compared with the 
whole population is a concern and reflects previous data 
highlighting lower recruitment of older women to BC clini-
cal trials.23 This lower uptake may be because older women 
have declined entry or may reflect appropriate exclusion 
from the trial due to existing comorbidities. A review of 
recruitment to 985 breast cancer treatment trials in Canada 
found that older women were less likely to be eligible for 
trials, physicians were less likely to have a discussion 
around trials with older women, and even when meeting 
eligibility criteria older women were less likely to be 
recruited.23 Conversely, a US study found that older breast 
cancer patients were equally likely to take part in treatment 
trials if they were eligible.24 Strategies to maximize uptake 
of older women are important since around a third of newly 
diagnosed breast cancers in both the United States and 
England occur in women older than 70 years.25,26
Our study population lived between 2 and 60 miles from 
the center, with a median distance of 8.6 miles. Distance 
from home to recruiting center was not cited as a factor for 
declining study participation. The BEST-Participation-
Study, a randomized trial testing an exercise intervention 
during radiotherapy for breast cancer, which involved 
attending a central location for an exercise class twice 
weekly for 12 weeks, reported distance from the center as a 
significant factor in recruitment.27 The difference between 
these trials is likely to reflect the fact we deliberately mini-
mized the travel burden to trial participants by hosting the 
supervised diet and exercise classes in a number of venues 
proximal to participants’ homes around the region. The 
reimbursement for transport costs in our study may have 
helped overcome difficulties with travel.
We sought to recruit women of any weight to the 
B-AHEAD trial and reported a comparable uptake between 
different BMI categories. This is consistent with an earlier 
small diet and exercise trial (n = 9).14 The remaining weight 
control trials among women of any weight have not reported 
whether there are any differences in uptake between these 2 
groups.15,28 The BEST-Participation-Study focused on exer-
cise to reduce fatigue and not weight control and also found 
no difference in BMI between participants and nonpartici-
pants.27 Ethnicity also did not affect recruitment in this trial; 
however, our population of BC patients are mainly white 
Caucasian. Previous UK and US studies have reported 
reduced uptake among ethnic groups in truly multicultural 
settings.29,30
We approached women across all levels of deprivation 
but found a lower uptake among the most deprived as seen 
in other BC treatment trials.31-33 This difference may reflect 
higher rates of comorbidity thus lower eligibility among 
more deprived communities.31 The survey by Brown and 
Moyer34 of more than 7000 adults in the United States 
found a lower understanding of clinical trials among 
patients with lower income and lower education levels, 
which may also have affected our recruitment seen here. It 
is recognized that increased deprivation levels are linked to 
poorer health behaviors, for example, lower levels of phys-
ical activity and higher rates of smoking,35 and previous 
UK research has found poorer survival after BC among 
more deprived women.36 Methods for improving engage-
ment in clinical trials among more deprived women must 
be developed and implemented. There is some evidence 
from other cancer trials that effective initiatives could 
include improving readability of leaflets or using video 
presentations instead of written materials, improved com-
munication skills of health care professionals, and using 
satellite clinics closer to patients’ homes.33 Schemes to 
offer financial assistance to reimburse the added cost of 
travel associated with cancer clinical trials have been 
shown to improve recruitment among patients with lower 
incomes and those living further away from the research 
center and this is an important area that all trials should 
consider to improve equality.37 The greater uptake among 
women with screen-detected cancers may also reflect the 
greater uptake among women from more affluent areas 
who are more likely to attend screening,38 are more moti-
vated to engage in positive health behaviors and perhaps 
more interested in diet and exercise.39,40
Previous research has reported that recommendation 
from the oncologist was an important factor for deciding to 
enter a trial.41 We did not collect data on the input of the 
oncologist within the different recruiting centers. However, 
future lifestyle trials should engage the support and enthusi-
asm of oncologists, in addition to the research nurses, to 
increase the likelihood that they promote the trial to poten-
tial participants. Adequate research staff levels are also cru-
cial after patients have been initially approached. Five 
percent of women approached regarding B-AHEAD were 
unable to be recontacted within the 12-week time frame for 
recruitment due to inadequate levels of recruiting staff.
We were unable to produce a CONSORT diagram as we 
failed to obtain full uptake data in all recruiting centers. 
This problem has previously been highlighted with cancer 
exercise trials42 and BC treatment trials.43 CONSORT 
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diagrams allow assessment of studies’ generalizability and 
future studies should endeavor to collect and publish full 
recruitment data. A limitation of the present paper is that the 
conclusions we have made for the UHSM patients may not 
be applicable to the other recruiting centers with different 
patient populations.
Here we present UK data showing successful recruit-
ment to a diet and exercise trial using the cancer research 
network, at a challenging time for BC patients soon after 
surgery, and among patients facing the prospect of chemo-
therapy. The data describe the population to which the out-
comes of the B-AHEAD study, to be published in a future 
article, will be applicable. Future studies should aim to 
gather complete uptake data from all centers and explore 
ways to engage older and lower socioeconomic women in 
interventions.
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